Article info
Clinical science
Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
- Correspondence to Dr Eydie Miller Ellis, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Eydie.Miller{at}uphs.upenn.edu
Citation
Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Publication history
- Received May 12, 2016
- Revised August 4, 2016
- Accepted August 10, 2016
- First published September 20, 2016.
Online issue publication
November 21, 2020
Article Versions
- Previous version (21 November 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/